Evidence map›Paper›PMID 33889008›Full record

ReviewJournal of inflammation research2021

Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications.

Adekunle Babajide Rowaiye, Okiemute Ajiroghene Okpalefe, Olukemi Onuh Adejoke, Joyce Oloaigbe Ogidigo, Oluwakemi Hannah Oladipo, Amoge Chidinma Ogu, Angus Nnamdi Oli, Samson Olofinase, Onyekachi Onyekwere, Abdullahi Rabiu Abubakar and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Adekunle Babajide RowaiyeDepartment of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.ORCID 0000-0002-8773-5944
Okiemute Ajiroghene OkpalefeDepartment of Genetics, Genomics, Bioinformatics, National Biotechnology Development Agency, Abuja, Nigeria.ORCID 0000-0003-1242-2158
Olukemi Onuh AdejokeDepartment of Medical Biotechnology, National Biotechnology Development Agency, Abuja, Nigeria.ORCID 0000-0002-5545-4662
Joyce Oloaigbe OgidigoBioresources Development Centre, Abuja, National Biotechnology Development Agency, Abuja, Nigeria.ORCID 0000-0003-3323-0657
Oluwakemi Hannah OladipoBioresources Development Centre, Ilorin, National Biotechnology Development Agency, Kwara State, Nigeria.ORCID 0000-0002-9921-8944
Amoge Chidinma OguDepartment of Medical Biotechnology, National Biotechnology Development Agency, Abuja, Nigeria.ORCID 0000-0003-3461-2737
Angus Nnamdi OliDepartment of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.ORCID 0000-0001-8519-2555
Samson OlofinaseDepartment of Genetics, Genomics, Bioinformatics, National Biotechnology Development Agency, Abuja, Nigeria.ORCID 0000-0003-4800-8354
Onyekachi OnyekwereBioresources Development Centre, Ubulu-Uku, National Biotechnology Development Agency, Delta State, Nigeria.ORCID 0000-0001-9655-9762
Abdullahi Rabiu AbubakarDepartment of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Bayero University, Kano, 700233, Nigeria.ORCID 0000-0002-9740-7856
Dilshad JahanDepartment of Hematology, Asgar Ali Hospital, Gandaria, Dhaka, 1204, Bangladesh.ORCID 0000-0002-3939-9093
Salequl IslamDepartment of Microbiology, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.ORCID 0000-0001-6131-4132
Siddhartha DuttaDepartment of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.ORCID 0000-0001-6525-5950
Mainul HaqueUnit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur, 57000, Malaysia.ORCID 0000-0002-6124-7993
National Primary Health Care Development Agency · NGNnamdi Azikiwe University · NGAll India Institute of Medical Sciences Jodhpur · INBayero University Kano · NGJahangirnagar University · BDNational Defence University of Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic constitutes an arduous global health challenge, and the increasing number of fatalities calls for the speedy pursuit of a remedy. This review emphasizes the changing aspects of the COVID-19 disease, featuring the cytokine storm's pathological processes. Furthermore, we briefly reviewed potential therapeutic agents that may modulate and alleviate cytokine storms. The literature exploration was made using PubMed, Embase, MEDLINE, Google scholar, and China National Knowledge Infrastructure databases to retrieve the most recent literature on the etiology, diagnostic markers, and the possible prophylactic and therapeutic options for the management of cytokine storm in patients hospitalized with COVID-19 disease. The causative agent, severe acute respiratory coronavirus-2 (SARS-CoV-2), continually threatens the efficiency of the immune system of the infected individuals. As the first responder, the innate immune system provides primary protection against COVID-19, affecting the disease's progression, clinical outcome, and prognosis. Evidence suggests that the fatalities associated with COVID-19 are primarily due to hyper-inflammation and an aberrant immune function. Accordingly, the magnitude of the release of pro-inflammatory cytokines such as interleukin (IL)-1, (IL-6), and tumor necrosis alpha (TNF-α) significantly differentiate between mild and severe cases of COVID-19. The early prediction of a cytokine storm is made possible by several serum chemistry and hematological markers. The prompt use of these markers for diagnosis and the aggressive prevention and management of a cytokine release syndrome is critical in determining the level of morbidity and fatality associated with COVID-19. The prophylaxis and the rapid treatment of cytokine storm by clinicians will significantly enhance the fight against the dreaded COVID-19 disease.

Indexed as

COVID-19cytokine stormfatalityhyper-inflammationSARS-CoV-2

Identifiers

PMID33889008
PMCPMC8057798
OpenAlexW3152491723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.